Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI

#neuromodulation in #rheumatoid #arthritis What is it? 👇 Autonomic & immune system interaction Who seeks this Rx? desperate pts w pain No Rx left Interested in technology #EULAR2025 @RheumNow @eular_org #D2T #RA https://t.co/XWWFiUK6Em

#vagal & #splenic #nerves most studied In #immune #system interaction #PNS can detect #inflammation use in #D2T #RA w active disease ? Key factors in #neurostimulation - many #EULAR2025 @RheumNow @eular_org #D2T in #RA session https://t.co/tCgpGtI5z2

The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy

#Vagal #nerve #stimulation Hand held device #BDMARD failure Plausible - improved pro inflammatory cytokines wears off benefit if stopped Attenuates in ~half over yrs Open label uncontrolled @RheumNow @eular_org #EULAR2025 Session D2T-RA https://t.co/98K5gwasHv

#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74

So we used to get taught about bimodal age distribution of RA onset - young people and old people. Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity Global Burden of Disease data #EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy

Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy

Do the sites of clinical onset of PsA (i.e., swelling) correspond to those that, at the time of enrollment in the study, showed evidence of joint tenderness and/or ultrasound-detected alterations compatible with inflammation? Of 28 incident PsA cases, 68% had prior subclinical https://t.co/rAZJU6Va5x

Even after having things laid out in a great debate, rheumatologists remain unconvinced by medical cannabis #EULAR2025 @RheumNow https://t.co/xMTvngS5N1